Loading...
XNAS
FLNA
Market cap29mUSD
Oct 26, Last price  
0.61USD
1D
-2.84%
1Q
-28.67%
Jan 2017
-84.08%
IPO
-99.54%
Name

Cassava Sciences Inc

Chart & performance

D1W1MN
XNAS:FLNA chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
84.14%
Shs. 5Y
13.09%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
53,918,00065,984,00063,725,00020,563,00016,809,00011,484,00010,890,00041,119,000000000000000
Net income
-91m
L+273.73%
6,188,00020,305,00015,347,000-3,467,000-12,023,000-2,613,000-3,446,00031,544,000-12,386,000-14,145,000-14,850,000-11,911,000-6,557,000-4,631,000-6,334,000-32,385,000-76,246,000-97,217,000-24,342,000-90,973,000
CFO
-32m
L-72.42%
-11,827,0002,231,00011,163,000-14,691,000-143,000-260,000-7,171,000-6,947,000-9,549,000-9,053,000-12,234,000-8,237,000-4,770,000-2,514,000-5,382,000-30,196,000-77,514,000-82,025,000-116,929,000-32,252,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

Key people

Claude Nicaise
Independent Chairman of the Board · since 2024
Richard Barry
President, Chief Executive Officer, Director · since 2024
Eric Schoen
Chief Financial Officer · since 2018
Angelique Bordey
Senior Vice President - Neuroscience · since 2025
Jack Moore
Senior Vice President - Clinical Development · since 2025
R. Christopher Cook
Chief Operating and Legal Officer · since 2025
Freda Nassif
Chief Business Officer · since 2024
Robert Anderson
Independent Director · since 2023
Dawn Bir
Independent Director · since 2025
Pierre Gravier
Independent Director · since 2023
Robert Gussin
Independent Director · since 2003
Michael O'Donnell
Independent Director · since 1998
Patrick Scannon
Independent Director · since 2007
URL
https://www.filanatx.com
IPO date
Jul 14, 2000
Employees
26
Domiciled in
US
Incorporated in
US
Legal address
c/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
7801 N. Capital of Texas Highway, Suite 260
Austin, TX 78731
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT